Non-coding Sequences Having No Known Regulatory Function Which Are Adaptors Or Linkers For Vector Or Gene Contruction Patents (Class 536/24.2)
-
Patent number: 6797512Abstract: A method for selecting packaging cells that express high levels of gag/pol is provided.Type: GrantFiled: September 12, 2001Date of Patent: September 28, 2004Assignee: Cell Genesys, Inc.Inventors: Ryan McGuinness, Luigi Naldini
-
Patent number: 6790942Abstract: Biologically active drug polymer derivatives, namely peptides or protein derivatives, are useful medicaments and are represented by the generic formula: RO—(CH2—CH2O)n—(CO)—NH—X—(CO)—NH—Z wherein R represents a lower alkyl group, n is an integer between 25 and 250, X when combined with adjcacent NH and CO groups represents a dipeptide residue, and Z when combined with the adjacent group represents a biologically active peptide or protein.Type: GrantFiled: June 5, 2001Date of Patent: September 14, 2004Assignee: Debio Recherche PharmaceutiqueInventors: Oddone Schiavon, Francesco Veronese, Paolo Caliceti, Piero Orsolini
-
Patent number: 6790946Abstract: A method of preparing an immobilized oligonucleotide having a free 3′-end comprises the steps of: i) preparing an oligonucleotide attached in a first position to a solid support via its 3′-end and having a free 5′-end; ii) binding said oligonucleotide in a second position remote from the 3′-end to the solid support; and iii) selectively releasing the 3′-end of the oligonucleotide from the solid support to obta the oligonucleotide attached to the support in said second position in a reversed orientation with a free 3′-end.Type: GrantFiled: September 12, 2001Date of Patent: September 14, 2004Assignee: Quiatech ABInventors: Marek Kwiatkowski, Ulf Landegren, Mats Nilsson
-
Patent number: 6780587Abstract: Methods and compositions are provided for diagnosing and treating Pseudoxanthoma elasticum (PXE) patients and PXE carriers. Methods and compositions are based on the discovery that PXE mutations are located in the MRP6 (ABCC6) gene.Type: GrantFiled: February 23, 2001Date of Patent: August 24, 2004Assignees: PXE International, Inc., The University of HawaiiInventors: Charles D. Boyd, Katalin Csiszar, Olivier LeSaux, Zsolt Urban, Sharon Terry
-
Patent number: 6762022Abstract: Disclosed are a number of methods that can be used in a variety of embodiments, including, creation of a nucleic acid terminated at one or more selected bases, sequence analysis of nucleic acids, mapping of sequence motifs within a nucleic acid, positional mapping of nucleic acid clones, and analysis of telomeric regions. The methods utilize double-stranded templates, and in most aspects involve a strand replacement reaction initiated at one or more random or specific locations created in a nucleic acid molecule, and in certain aspects utilizing an oligonucleotide primer.Type: GrantFiled: March 6, 2001Date of Patent: July 13, 2004Assignee: The Regents of the University of MichiganInventors: Vladimir L. Makarov, John P. Langmore
-
Patent number: 6750010Abstract: The present invention is directed to methods of detecting the presence of a bipolar mood disorder susceptibility locus in an individual, comprising analyzing a sample of DNA for the presence of a DNA polymorphism on the short arm of chromosome 18 between the telomere and D18S481, wherein the DNA polymorphism is associated with a form of bipolar mood disorder. The invention for the first time provides strong evidence of a susceptibility gene for bipolar mood disorder that is located in the terminal 5 cM region of the short arm of chromosome 18. The disclosure describes the use of linkage analysis and genetic markers in this 5 cM region to fine map the region and the use of genetic markers to genetically diagnose (genotype) bipolar mood disorder in individuals, to confirm phenotypic diagnoses of bipolar mood disorder, to determine appropriate treatments for patients with particular genotypic subtypes.Type: GrantFiled: November 24, 1997Date of Patent: June 15, 2004Assignees: The Regents of the University of California, Univerisity of Costa RicaInventors: Nelson B. Freimer, Lodewijk Sandkuijl, Pedro Leon, Victor I. Reus, Michael Escamilla, Lynne Allison McInnes, Susan K. Service
-
Patent number: 6746845Abstract: Serial analysis of gene expression, SAGE, a method for the rapid quantitative and qualitative analysis of transcripts is provided. Short defined sequence tags corresponding to expressed genes are isolated and analyzed. Sequencing of over 1,000 defined tags in a short period of time (e.g., hours) reveals a gene expression pattern characteristic of the function of a cell or tissue. Moreover, SAGE is useful as a gene discovery tool for the identification and isolation of novel sequence tags corresponding to novel transcripts and genes.Type: GrantFiled: March 14, 2002Date of Patent: June 8, 2004Assignee: The Johns Hopkins UniversityInventors: Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Lin Zhang
-
Patent number: 6743582Abstract: The invention employs an unlabeled signal primer comprising a 5′ adapter sequence for detection of nucleic acid target sequences. The detection system further comprises a reporter probe, the 3′ end of which hybridizes to the complement of the 5′ adapter sequence of the signal primer to produce a 5′ overhang. Polymerase is used to fill in the overhang and synthesize the complement of the 5′ overhang of the reporter probe. Synthesis of the reporter probe complement is detected, either directly or indirectly, as an indication of the presence of the target.Type: GrantFiled: June 28, 2001Date of Patent: June 1, 2004Assignee: Becton, Dickinson and CompanyInventors: James G. Nadeau, Tobin J. Hellyer
-
Patent number: 6743906Abstract: The present invention identifies the PPP2R1B gene, as a human tumor suppressor gene. Sequencing of the PPP2R1B revealed that the gene is located on human chromosome 11q22-24 and that gene were mutated in tumors and tumor cell lines, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in lung, colon, breast and cervical cancer cells. Methods for diagnosing and treating cancers related to this tumor suppressor also are disclosed.Type: GrantFiled: October 1, 1999Date of Patent: June 1, 2004Assignee: Board of Regents, The University of TexasInventors: Glen A. Evans, Steven Siqing Wang, Edward D. Esplin, Jia Ling Li, Liying Huang
-
Patent number: 6734293Abstract: The invention provides novel extracts, proteins, and complexes that improve the polymerization activity of nucleic acid polymerases. Included within the aspects of the invention are methods for identifying compositions with a polymerase enhancing activity, methods for purifying and using these compositions, and specific extracts, proteins, and complexes that function to enhance polymerase activity. As an example, specifically described is nucleotide and amino acid sequence information for a Pyrococcus furiousus PEF (P45), which was used to produce a recombinant PEF.Type: GrantFiled: September 20, 1999Date of Patent: May 11, 2004Assignee: StratageneInventors: Holly Hogrefe, Connie J. Hansen
-
Patent number: 6720166Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.Type: GrantFiled: June 5, 1995Date of Patent: April 13, 2004Assignee: Abbott LaboratoriesInventors: John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, James Carl Erker, Sheri L. Buijk, Isa K. Mushahwar
-
Patent number: 6706874Abstract: A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5′-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G→A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.Type: GrantFiled: December 21, 2001Date of Patent: March 16, 2004Inventors: George Kukolj, Arnim Pause
-
Patent number: 6706477Abstract: The present invention relates to novel methods for the identification of antigens recognized by cytotoxic T cells (CTLs) and specific for human tumors, cancers, and infected cells, and the use of such antigens in immunogenic compositions or vaccines to induce regression of tumors, cancers, or infections in mammals, including humans. The invention encompasses methods for induction and isolation of cytotoxic T cells specific for human tumors, cancers and infected cells, and for improved selection of genes that encode the target antigens recognized by these specific T cells. The invention also relates to differential display methods that improve resolution of, and that reduce the frequency of false positives of DNA fragments that are differentially expressed in tumorous, cancerous, or infected tissues versus normal tissues. The invention further relates to the engineering of recombinant viruses as expression vectors for tumor, cancer, or infected cell-specific antigens.Type: GrantFiled: April 2, 2001Date of Patent: March 16, 2004Assignee: University of RochesterInventor: Maurice Zauderer
-
Patent number: 6692938Abstract: A peptide has an amino acid sequence having more than 80% homology with the amino acid sequence listed as SEQ ID NO:4. A nucleic acid molecule has more than 80% homology with one of the nucleic acid sequences listed as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. Ligands, anti-ligands, cells vectors relating to the peptide and/or nucleic acid molecule are also used.Type: GrantFiled: August 24, 2001Date of Patent: February 17, 2004Assignee: Euroscreen, S.A.Inventors: Michel Samson, Marc Parmentier, Gilbert Vassart, Frederick Libert
-
Patent number: 6692965Abstract: The invention is directed to reliable and efficient detection of mRNAs as well as other RNAs in living cells and its use to identify and, if desired, separate cells based on their desired characteristics. Such methods greatly simplify and reduce the time necessary to carry out previously-known procedures, and offers new approaches as well, such as selecting cells that generate a particular protein or antisense oligonucleotide, generating cell lines that express multiple proteins, generating cell lines with knock-out of one or more protein, and others.Type: GrantFiled: November 22, 2000Date of Patent: February 17, 2004Assignee: Chromocell CorporationInventors: Kambiz Shekdar, Gunter Blobel
-
Patent number: 6686152Abstract: Methods for the multiplexed detection of known, selected nucleotide target sequences are provided. Detection involves the release of identifying tags as a consequence of target recognition. The methods include the use of electrophoretic tag probes or e-tag probes, comprising a detection region and a mobility-defining region called the mobility modifier, both linked to a target-binding moiety. In practicing the methods, the target-binding moiety of the e-tag probes hybridizes to complementary target sequences followed by nuclease cleavage of the e-tag probes and release of detectable e-tags or e-tag reporters. The mixture is exposed to a capture agent which binds uncleaved and/or partially cleaved e-tag probes, followed by electrophoretic separation. In a multiplexed assay, different released e-tag reporters may be separated and detected providing for target identification.Type: GrantFiled: April 2, 2001Date of Patent: February 3, 2004Assignee: Aclara Biosciences, Inc.Inventors: Sharat Singh, Huan Tian
-
Patent number: 6683170Abstract: The fiber protein of adenovirus has been genetically altered via attachment at the carboxyl end of a peptide linker, preferably up to 26 amino acids in length which forms a random coil, which can be used to attach a non-adenovirus ligand altering the binding specificity of the fiber protein. Examples of ligands include peptides which are selectively bound by a targeted cell so that the modified fiber protein is internalized by receptor-mediated endocytosis, and peptides which can act as an universal coupling agent, for example, biotin or strepavidin. The linker is designed to not interfere with normal trimerization of fiber protein, to avoid steric hindrance of binding of the fiber protein to a targeted cell, and to serve as a site to introduce new peptide sequence.Type: GrantFiled: July 13, 2001Date of Patent: January 27, 2004Assignee: UAB Research FoundationInventors: David T. Curiel, Jeffrey A. Engler
-
Patent number: 6677121Abstract: Disclosed is a method for the comprehensive analysis of nucleic acid samples and a detector composition for use in the method. The method, referred to as Fixed Address Analysis of Sequence Tags (FAAST), involves generation of a set of nucleic acid fragments having a variety of sticky end sequences; indexing of the fragments into sets based on the sequence of sticky ends; associating a detector sequence with the fragments; sequence-based capture of the indexed fragments on a detector array; and detection of the fragment labels. Generation of the multiple sticky end sequences is accomplished by incubating the nucleic acid sample with one or more nucleic acid cleaving reagents. The indexed fragments are captured by hybridization and coupling, preferably by ligation, to a probe. The method allows a complex sample of nucleic acid to be quickly and easily cataloged in a reproducible and sequence-specific manner.Type: GrantFiled: May 15, 2001Date of Patent: January 13, 2004Assignees: Agilix Corporation, Yale UniversityInventors: Paul M. Lizardi, Matthew E. Roth, Li Feng, Cesar E. Guerra, Shane C. Weber, Joseph C. Kaufman, Darin R. Latimer
-
Patent number: 6670188Abstract: The invention provides improved methods and products based on adenoviral materials which can advantageously be used in for instance gene therapy. In one aspect an adenoviral vector is provided which has no overlap with a suitable packaging cell line which is another aspect of the invention. This combination excludes the possibility of homologous recombination, thereby excluding the possibility of the formation of replication competent adenovirus. In another aspect an adenovirus based helper construct which by its size is incapable of being encapsidated. This helper virus can be transferred into any suitable host cell making it a packaging cell. Further, a number of useful mutations to adenoviral based materials and combinations of such mutations are disclosed, which all have in common the safety of the methods and the products, in particular avoiding the production of replication competent adenovirus and/or interference with the immune system. Further, a method of intracellular amplification is provided.Type: GrantFiled: April 24, 1998Date of Patent: December 30, 2003Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Patent number: 6653127Abstract: Covalent HCV NS4A-NS3 complexes comprising the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.Type: GrantFiled: October 6, 2000Date of Patent: November 25, 2003Assignee: Schering CorporationInventors: Bruce A. Malcolm, S. Shane Taremi, Patricia C. Weber, Nanhua Yao
-
Patent number: 6642025Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the lorf2 gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: July 13, 2001Date of Patent: November 4, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6632611Abstract: The presently claimed invention provides methods and kits for amplifying a target sequence from within a nucleic acid population. The presently claimed invention provides selection probes which are complementary to at least a portion of said target sequence and mechanisms for adding a probe sequence to the 3′ end of a target sequence that is hybridized to a selection probe. The added 3′ probe sequence and a probe sequence added at the 5′ end of the target by adaptor ligation allow for selective amplification of the target sequence.Type: GrantFiled: July 20, 2001Date of Patent: October 14, 2003Assignee: Affymetrix, Inc.Inventors: Xing Su, Shoulian Dong
-
Patent number: 6627437Abstract: Hitherto undiscovered 3′ sequence of GBV confers infectivity in tamarins on otherwise non-infective GBV genome. HCV sequences may be substituted within an infective GBV genome to provide for in vivo assays for agents able to modulate HCV activity.Type: GrantFiled: May 25, 2000Date of Patent: September 30, 2003Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventor: Cinzio Traboni
-
Patent number: 6620588Abstract: The present invention provides methods for screening compounds capable of modulating nucleic acid-modifying enzymatic activity, including topoisomerase activity.Type: GrantFiled: May 31, 2000Date of Patent: September 16, 2003Assignee: Salk Institute for Biological StudiesInventors: Frederic Bushman, Young Hwang
-
Patent number: 6617130Abstract: A heterologous polypeptide is expressed under the control of a DNA construct containing a promoter region derived from a cyanophage or cyanobacteria promoter. In one embodiment, such a promoter region is operably linked to an operator region derived from an operator native to the host cell. In another embodiment, the operator region is positioned upstream of the promoter region.Type: GrantFiled: March 31, 2000Date of Patent: September 9, 2003Assignee: Monsanto Technology LLCInventors: Gregg Bogosian, Julia P. O'Neil, Katherine C. Terlesky
-
Patent number: 6596491Abstract: Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.Type: GrantFiled: May 14, 2001Date of Patent: July 22, 2003Assignee: Gilead Sciences, Inc.Inventors: Brian Hicke, Stephen Warren, David Parma, Larry Gold
-
Patent number: 6596856Abstract: Nucleic acid labeling compounds containing heterocyclic derivatives are disclosed. The heterocyclic derivative containing compounds are synthesized by condensing a heterocyclic derivative with a cyclic group (e.g. a ribofuranose derivative). The labeling compounds are suitable for enzymatic attachment to a nucleic acid, either terminally or internally, to provide a mechanism of nucleic acid detection.Type: GrantFiled: February 9, 2001Date of Patent: July 22, 2003Assignee: Affymetrix, Inc.Inventors: Glenn McGall, Anthony D. Barone
-
Patent number: 6586584Abstract: Primers and probes derived from the 5′ untranslated region of the HCV genome which facilitate detection and/or quantification of all presently known genotypes of HCV. Disclosed sequences may be used in a variety of primer and probe constructs for amplification and/or detection of HCV nucleic acids.Type: GrantFiled: January 29, 2001Date of Patent: July 1, 2003Assignee: Becton, Dickinson and CompanyInventors: Ray A. McMillian, Tobin J. Hellyer
-
Patent number: 6586186Abstract: The present invention generally provides a rapid efficient method for analyzing polymorphic or biallelic markers, and arrays for carrying out these analyses. In general, the methods of the present invention employ arrays of oligonucleotide probes that are complementary to target nucleic acids which correspond to the marker sequences of an individual. The probes are typically arranged in detection blocks, each block being capable of discriminating the three genotypes for a given marker, e.g., the heterozygote or either of the two homozygotes. The method allows for rapid, automatable analysis of genetic linkage to even complex polygenic traits.Type: GrantFiled: August 24, 2001Date of Patent: July 1, 2003Assignee: Affymetrix, Inc.Inventors: Robert J. Lipshutz, Ronald Sapolsky, Ghassan Ghandour
-
Patent number: 6582957Abstract: The nucleotide and corresponding amino acid sequences are reported for a novel class of mammalian lipoxygenase proteins. The novel lipoxygenase encoding polynucleotides were obtained from human gene trap clones and human cDNA libraries.Type: GrantFiled: April 12, 2000Date of Patent: June 24, 2003Assignee: Lexicon Genetics IncorporatedInventors: C. Alexander Turner, Jr., Brian Zambrowicz, Michael Nehls, Glenn Friedrich, Arthur T. Sands
-
Patent number: 6582918Abstract: This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.Type: GrantFiled: May 8, 2001Date of Patent: June 24, 2003Assignee: Gilead Sciences, Inc.Inventors: Nebojsa Janjic, Larry Gold
-
Patent number: 6576420Abstract: The invention provides a method for diagnosis of, and determining a prognosis for, cancer causatively associated with derangements of chromosome 9p21. Underlying the invention is the discovery that such derangements have their genesis in deletions occurring centromeric to STS 3.21, most often including breakpoints in exon 8 and/or between exons 4 and 5 of the gene which codes for methylthioadenosine phosphorylase. As the cancer and tumor development advance, deletions in 9p21 progress centromerically from the genesis point toward the gene encoding p16. Thus, the method of the invention is performed by determining whether (a) portions of the 9p21 region including and telomeric to STS 3.21 are deleted; and (b) portions of the 9p21 region centromeric to STS 3.Type: GrantFiled: June 17, 1999Date of Patent: June 10, 2003Assignee: Regents of the University of CaliforniaInventors: Dennis A. Carson, Mathias Schmid, Carlos J. Carrera
-
Patent number: 6562955Abstract: An oligonucleotide for detection or amplification of a gene selected from the group consisting of Vibrio parahaemolyticus thermostable direct hemolysin-related hemolysin genes (trh1 and trh2) and Vibrio parahaemolyticus thermostable direct hemolysin gene (tdh2) or RNA derived therefrom is provided. Further, method for detecting trh1, trh2 or tdh2 using said oligonucleotide is provided.Type: GrantFiled: March 15, 2001Date of Patent: May 13, 2003Assignee: Tosoh CorporationInventors: Tetsuya Ishizuka, Takahiko Ishiguro, Juichi Saitoh
-
Publication number: 20030087339Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.Type: ApplicationFiled: January 21, 1998Publication date: May 8, 2003Inventors: JIAN NI, CRAIG A. ROSEN, VISHVA M. DIXIT, REINER L. GENTZ, JOSEPH J. KENNY
-
Patent number: 6558908Abstract: Methods and kits for labeling nucleic acids are provided. In the subject methods, an oligonucleotide tagged nucleic acid comprising an oligonucleotide tag is first generated. The oligonucleotide tagged nucleic acid is then contacted under hybridization conditions with a labeled oligonucleotide complementary to the oligonucleotide tag, yielding a labeled nucleic acid. The kits of the subject invention at least include a primer for use in enzymatically generating an oligonucleotide tagged target nucleic acid, where the primer generally at least includes an oligo dT region and the oligonucleotide tag, and a labeled oligonucleotide complementary to the oligonucleotide tag. The subject methods and kits find use in a variety of applications, and are particularly suited for use in gene expression analysis applications.Type: GrantFiled: May 18, 2001Date of Patent: May 6, 2003Assignee: Agilent Technologies Inc.Inventors: Paul K. Wolber, Karen W. Shannon
-
Patent number: 6558927Abstract: The invention concerns a method for the modification, cloning and amplification of cDNAs which are complete at their 5′ end which is essentially characterized in that the first strand cDNA synthesis is carried out in the presence of manganese2+ ions or manganese2+ is added as an additive at a later time. The CAP structure at the 5′ end of the reversely transcribed mRNA triggers the attachment of deoxy-cytosines to the 3′ end of the cDNA with high efficiency. In a preferred embodiment a controlled ribonucleotide tailing is carried out with the aid of terminal transferase following the first strand cDNA synthesis.Type: GrantFiled: May 5, 2000Date of Patent: May 6, 2003Assignee: Roche Diagnostics CorporationInventors: Manfred W. Mueller, Wolfgang M. Schmidt
-
Publication number: 20030082799Abstract: A vector which is characterized in containing each of the following elements:Type: ApplicationFiled: October 10, 2002Publication date: May 1, 2003Inventors: Masanori Takayama, Yoshiko Nomura, Ikunoshin Kato
-
Patent number: 6548656Abstract: This application provides frame-adjusting linkers FAL-1 and FAL-2 which are single-stranded DNA consisting of a palindrome base sequence of SEQ ID NO. 1 and SEQ ID NO. 2, respectively. These linkers are able to prepare mutant DNA sequences having correct translation frames before and behind the any cleaved sites, therefore, time and cost for preparation of mutant protein, etc. can be greatly reduced.Type: GrantFiled: November 26, 2001Date of Patent: April 15, 2003Assignee: Japan Science and Technology CorporationInventor: Toshiaki Oda
-
Patent number: 6548251Abstract: A method of inhibiting at least one molecular process in a sample, comprising administering to the sample an oligonucleotide or polynucleotide containing at least one monomeric unit having formula (I): A—Xn (I) wherein A is an organic moiety, n is at least 1, and each X is independently selected from the group consisting of —NRCOCONu, —NHCOCR2CR2CONu, —NHCOCR═CRCONu, and —NHCOSSCONu, wherein each R independently represents H or a substituted or unsubstituted alkyl group, and Nu represents a nucleophile, or a salt of the compound.Type: GrantFiled: September 5, 2000Date of Patent: April 15, 2003Assignee: Fidelity Systems, Inc.Inventors: Sergei A. Kozyavkin, Andrei G. Malykh, Nikolai N. Polouchine, Alexei I. Slesarev
-
Publication number: 20030059412Abstract: Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed.Type: ApplicationFiled: December 8, 1997Publication date: March 27, 2003Inventors: DARWIN J. PROCKOP, RUTH F. PEREIRA, DENNIS B. LEEPER, MICHAEL D. O'HARA, JOSEPH KULKOSKY, DONALD PHINNEY, ALEXEY LAPTEV
-
Patent number: 6528285Abstract: The invention concerns a plasmid having a replication mode which is not of the RCR type, and capable of being transferred in stable form into host lactic acid bacteria belonging at least to three different kinds.Type: GrantFiled: September 18, 2000Date of Patent: March 4, 2003Assignee: TexelInventors: Franck Biet, Yves Cenatiempo, Christophe Fremaux
-
Patent number: 6524815Abstract: The invention relates to the isolation and cloning of the VE-cadherin promoter. It also relates to transformed cells and transgenic animals containing the VE-cadherin promoter. The VE-cadherin promoter of the invention is particularly useful for the tissue-specific expression of a gene of interest in the vascular endothelium.Type: GrantFiled: August 27, 1999Date of Patent: February 25, 2003Assignee: Commissariat a l'Energie Atomique-C.E.A.Inventors: Philippe Huber, Monique Laurent, Sylvie Gory
-
Patent number: 6521427Abstract: The present invention relates generally to the fields of oligonucleotide synthesis. More particularly, it concerns the assembly of genes and genomes of completely synthetic artificial organisms. Thus, the present invention outlines a novel approach to utilizing the results of genomic sequence information by computer directed gene synthesis based on computing on the human genome database. Specifically, the present invention contemplates and describes the chemical synthesis and resynthesis of genes defined by the genome sequence in a host vector and transfer and expression of these sequences into suitable hosts.Type: GrantFiled: May 12, 2000Date of Patent: February 18, 2003Assignee: Egea Biosciences, Inc.Inventor: Glen A. Evans
-
Patent number: 6521601Abstract: A method and pharmaceutical composition for inhibiting viral replication in infected cells are described. The pharmaceutical composition includes a DNA fragment which has covalently linked strands. The DNA fragment contains a 6-30 basepair region whose sequence corresponds to that of a regulatory element in a virus. The method includes introducing a fragment into the cell in an amount sufficient to inhibit replication of the virus in the cell.Type: GrantFiled: April 14, 1992Date of Patent: February 18, 2003Assignee: Signal Pharmaceuticals, Inc.Inventor: Mark D. Carman
-
Patent number: 6521419Abstract: A specific locus (hot spot) for recombinant gene expression has been identified in the genome of Chinese hamster ovary cells. A DNA vector containing the hot spot causes high levels of recombinant gene expression following transfection and stable integration. The selection and cloning of the specific locus and the expression of recombinant genes is disclosed, as are the DNA vectors and the host cells.Type: GrantFiled: August 31, 1999Date of Patent: February 18, 2003Inventors: Kanakaraju Koduri, John T. Miller, Pallaiah Thammana
-
Patent number: 6515120Abstract: The present invention relates to methods for sequencing a polymeric biomolecule and methods for structurally characterizing the same comprising using aptamers. In a preferred embodiment of this invention, these methods relate to using the single polymeric biomolecule. The invention also relates to a method for selecting aptamers useful for sequencing nucleic acids and aptamers generated by the method. The invention also provides aptamers that recognize and bind to AMP, dAMP, GMP, dGMP, CMP and dCMP.Type: GrantFiled: May 25, 2000Date of Patent: February 4, 2003Assignee: Praelux IncorporatedInventors: Jae-Gyu Kwagh, John J. Macklin, Paul G. Mitsis, Kevin M. Ulmer
-
Patent number: 6506561Abstract: A method of obtaining a library of tags able to define a specific state of a biological sample, such as a tissue or a cell culture. The present method provides an important advantage over other methods used to analyze gene expression in that libraries may be generated from tiny amounts of cells, e.g., from 30,000-100,000 cells.Type: GrantFiled: April 29, 1999Date of Patent: January 14, 2003Assignees: Commissariat a l'Energie Atomique, Centre National de la Recherche Scientifique-CNRSInventors: Lydie Cheval, Jean-Marc Elalouf, Bérangère Virlon
-
Patent number: 6506595Abstract: This invention relates to a DNA comprising a nucleotide sequence encoding a fusion protein, wherein the fusion protein comprises: a sequence of signal peptide for Bacillus cell wall protein (CWP); a tag sequence for separation and purification of the fusion protein; a linker sequence; a sequence for chemical or enzymatic cleavage; and an exogenous polypeptide sequence, the sequences being linked in order, the signal peptide, tag and linker being optional sequences; and wherein the nucleotide sequence encoding a fusion protein is ligated to 3′-end of a nucleic acid sequence comprising a Bacillus promoter region; to a vector comprising the DNA; to a bacterium belonging to the genus Bacillus comprising the vector; and to a process for preparation of a useful polypeptide by culture of the bacterium.Type: GrantFiled: March 26, 1999Date of Patent: January 14, 2003Assignees: Itoham Foods Inc.Inventors: Seiji Sato, Naohiko Higashikuni, Toshiyuki Kudo, Masaaki Kondo
-
Patent number: 6500647Abstract: The present invention relates to a recombinant expression vector which is prepared by inserting a human parathyroid hormone gene containing a urokinase-specific cleavage site into an L-arabinose inducible vector containing a phosphoribulokinase gene fragment of Rhodabacter sphaeroides or its mutated gene as a fusion partner, or its mutate gene as a fusion partner, a recombinant microorganism transformed with the said expression vector, and a process for preparing human parathyroid hormone on a large scale by cultivating the said microorganism in a medium containing L-arabinose. In accordance with the invention, a recombinant human PTH having the same activity of the native human PTH can be prepared in a high yield through the precise control of induction by a manufacturing process which comprises a step of inducing expression of fusion protein in the microorganism transformed with the recombinant expression vector by L-arabinose.Type: GrantFiled: January 20, 2000Date of Patent: December 31, 2002Assignee: Mogam Biotechnology Research InstituteInventors: Eun-Kyung Jung, Doo-Hong Park, Soo-Il Chung
-
Patent number: 6489114Abstract: A process is provided for labeling with signal amplification a ribonucleic acid (RNA), comprising fragmenting the RNA to form RNA fragments, fixing a first ligand to a terminal phosphate located at least one of the 3′ end and the 5′ end of each of a plurality of the RNA fragments, the terminal phosphate having been released during the fragmentation, and binding a plurality of labeling agents to the first ligand on each of a plurality of the fragments.Type: GrantFiled: December 18, 2000Date of Patent: December 3, 2002Assignees: BIO Merieux, Affymetrix, Inc.Inventors: Ali Laayoun, Duc Do, Charles G. Miyada